↓ Skip to main content

The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: a double-blinded, randomized, placebo-controlled trial

Overview of attention for article published in Arthritis Research & Therapy, January 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)
  • High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

news
2 news outlets
twitter
3 X users

Citations

dimensions_citation
24 Dimensions

Readers on

mendeley
86 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: a double-blinded, randomized, placebo-controlled trial
Published in
Arthritis Research & Therapy, January 2017
DOI 10.1186/s13075-016-1207-7
Pubmed ID
Authors

Yasumori Izumi, Manabu Akazawa, Yukihiro Akeda, Shigeto Tohma, Fuminori Hirano, Haruko Ideguchi, Ryutaro Matsumura, Tomoya Miyamura, Shunsuke Mori, Takahiro Fukui, Nozomi Iwanaga, Yuka Jiuchi, Hideko Kozuru, Hiroshi Tsutani, Kouichirou Saisyo, Takao Sugiyama, Yasuo Suenaga, Yasumasa Okada, Masao Katayama, Kenji Ichikawa, Hiroshi Furukawa, Kenji Kawakami, Kazunori Oishi, Kiyoshi Migita

Abstract

Pneumococcal pneumonia is the most frequent form of pneumonia. We herein assessed the effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in the prevention of pneumonia overall in rheumatoid arthritis (RA) patients at risk for infections. We hypothesized that PPSV23 vaccination is superior in preventing pneumococcal pneumonia compared with placebo in RA patients. A prospective, multicenter, double-blinded, randomized, placebo-controlled (1:1) trial was conducted across departments of rheumatology in Japanese National Hospital Organization hospitals. RA patients (n = 900) who had been treated with biological or immunosuppressive agents were randomly assigned PPSV23 or placebo (sodium chloride). The primary endpoints were the incidences of all-cause pneumonia and pneumococcal pneumonia. The secondary endpoint was death from pneumococcal pneumonia, all-cause pneumonia, or other causes. Cox regression models were used to estimate the risk of pneumonia overall for the placebo group compared with the vaccine group. Seventeen (3.7%) of 464 patients in the vaccine group and 15 (3.4%) of 436 patients in the placebo group developed pneumonia. There was no difference in the rates of pneumonia between the two study groups. The overall rate of pneumonia was 21.8 per 1000 person-years for patients with RA. The presence of interstitial pneumonia (hazard ratio: 3.601, 95% confidence interval: 1.547-8.380) was associated with an increased risk of pneumonia in RA patients. PPSV23 does not prevent against pneumonia overall in RA patients at relative risk for infections. Our results also confirm that the presence of interstitial lung disease is associated with pneumonia in Japanese patients with RA. UMIN-CTR UMIN000009566 . Registered 17 December 2012.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 86 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 86 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 17 20%
Student > Ph. D. Student 11 13%
Student > Bachelor 11 13%
Student > Master 8 9%
Student > Doctoral Student 6 7%
Other 15 17%
Unknown 18 21%
Readers by discipline Count As %
Medicine and Dentistry 37 43%
Immunology and Microbiology 5 6%
Pharmacology, Toxicology and Pharmaceutical Science 5 6%
Biochemistry, Genetics and Molecular Biology 4 5%
Agricultural and Biological Sciences 2 2%
Other 9 10%
Unknown 24 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 February 2017.
All research outputs
#1,981,630
of 25,377,790 outputs
Outputs from Arthritis Research & Therapy
#318
of 3,380 outputs
Outputs of similar age
#40,300
of 422,427 outputs
Outputs of similar age from Arthritis Research & Therapy
#5
of 49 outputs
Altmetric has tracked 25,377,790 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,380 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.2. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 422,427 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 49 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.